Zelluna ASA Successfully Registering Share Capital Increase
Recently, an essential update emerged from Zelluna ASA regarding an important financial milestone. The company has successfully registered a share capital increase of NOK 0.70 by issuing seven new shares, each holding a par value of NOK 0.10. This significant step forward reflects the company’s commitment to scaling its operations and solidifying its financial foundation.
Details of the Share Capital Increase
The share capital increase was officially registered with the Norwegian Register of Business Enterprises, marking a pivotal moment for Zelluna ASA. Following this increase, the total share capital of the company stands at NOK 20,227,066, distributed across 202,270,660 shares. This restructured capital will enable the company to optimize its financial strategy and support its innovative endeavors.
Purpose of the Capital Increase
One of the principal reasons for this capital enhancement is to set the stage for a planned reverse share split. By augmenting the share capital, Zelluna ASA aims to achieve a more favorable share ratio, which is crucial for this forthcoming corporate maneuver. The details surrounding the reverse share split will be released in an upcoming notice, allowing stakeholders to stay informed about future changes.
Looking Forward: Zelluna’s Ambitious Mission
Zelluna ASA is not just focused on financial growth; the company is dedicated to delivering groundbreaking treatments aimed at curing advanced solid cancers. Their mission is commendable: to provide safe and effective solutions to patients globally. At the heart of their strategy is the pioneering development of “off the shelf” T cell receptor (TCR) guided natural killer (NK) cell therapies, branded as TCR-NK.
Innovative TCR-NK Platform
The TCR-NK platform harnesses the incredible potential of the immune system, offering a unique mode of action and a broad capacity to detect various types of tumors. One of Zelluna's flagship products is the world’s first MAGE-A4 targeting “off the shelf” TCR-NK, aimed at treating multiple solid cancers. This innovative pipeline promises a series of products that can potentially transform cancer treatment.
Management and Expertise Driving Success
Zelluna ASA is guided by a team of seasoned biotech entrepreneurs who bring extensive knowledge in the development of TCR and cell-based therapies. Their experience encompasses everything from discovery to clinical development of therapies that are now available on the market. This deep expertise is instrumental in propelling Zelluna’s cutting-edge research and ambitious goals.
Contact Information for Inquiries
For any inquiries related to Zelluna ASA and its initiatives, stakeholders are encouraged to reach out to Hans Vassgård Eid, the Chief Financial Officer, via email at hans.eid@zelluna.com or by phone at +47 482 48632.
Frequently Asked Questions
What is the recent development regarding Zelluna ASA?
Zelluna ASA has registered a share capital increase, enhancing its financial foundation.
What is the purpose of the share capital increase?
The increase aims to achieve an optimal ratio for an upcoming reverse share split.
How does Zelluna ASA plan to revolutionize cancer treatment?
Through innovative therapies that harness the immune system, specifically using TCR-NK technology.
Who leads the company in its research initiatives?
Zelluna ASA is managed by a team of experienced biotech entrepreneurs specializing in cell-based therapies.
How can I contact Zelluna ASA for more information?
You can reach out to Hans Vassgård Eid at hans.eid@zelluna.com or call +47 482 48632.
